BLIN vs XBIO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 02, 2026

BLIN

60.1
AI Score
VS
BLIN Wins

XBIO

56.0
AI Score

Investment Advisor Scores

BLIN

60score
Recommendation
HOLD

XBIO

56score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric BLIN XBIO Winner
Forward P/E 12.1507 0 Tie
PEG Ratio 0 0 Tie
Revenue Growth 2.0% 12.0% XBIO
Earnings Growth 12.5% 0.0% BLIN
Tradestie Score 60.1/100 56.0/100 BLIN
Profit Margin -8.6% -75.9% BLIN
Beta 1.00 1.00 Tie
AI Recommendation HOLD HOLD Tie

Relative Price Performance (Last 90 Days)

BLIN 1M: -13.3% · 3M: -37.5% XBIO 1M: -47.3% · 3M: -21.4%

Current Technical Phase

BLIN

Markdown
Sell / avoid

Price below a falling SMA50 (slope -12.7%), weak momentum, RSI 40

RSI (14): 40.2 · Price: $0.85

XBIO

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 35

RSI (14): 34.8 · Price: $2.24

Fundamentals Snapshot

Metric BLIN XBIO
Market Cap — —
Forward P/E 6.9 -6.6
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.0% 0.1%
Gross Margin 0.7% 1.0%
Operating Margin -0.1% -1.5%
EPS -0.10 -1.12
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, BLIN is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.